Pacira Pharma (PCRX): Coming Months May Be Challenging, Sticking To Buy - Mizuho
Tweet Send to a Friend
Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) and cut her price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE